Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression

Life Sciences

Volumn 88, Issue 23-24, 2011, Pages 1063-1069

  Xu, Huanli ^a,b   Inagaki, Yoshinori ^a   Seyama, Yasuji ^a   Hasegawa, Kiyoshi ^a   Sugawara, Yasuhiko ^a   Du, Guanhua ^b   Wang, Fengshan ^c   Tang, Wei ^a   Kokudo, Norihiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

catenin; KL 6 MUC1; Pancreatic ductal carcinoma; RNA interference; Wnt signal pathway

Indexed keywords

BETA CATENIN; CYCLIN D1; MUCIN 1; SMALL INTERFERING RNA; UVOMORULIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; METASTASIS; ONCOGENE C MYC; PANCREAS CARCINOMA; PANCREAS DUCT CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR GROWTH; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79957577485     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.03.021     Document Type: Article

References (29)

1. Behrens J. The role of the Wnt signaling pathway in colorectal tumorigenesis. Biochem Soc Trans 2005;33:672-5. (Pubitemid 41160836)
2. George SJ, Dwivedi A. MMPs, cadherins, and cell proliferation. Trends Cardiovasc Med 2004;14:100-5. (Pubitemid 38569676)
3. Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y, et al. Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol 2006;12:54-9. (Pubitemid 43126083)
4. Heiser PW, Cano DA, Landsman L, Kim GE, Kench JG, Klimstra DS, et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology 2008;135:1288-300.
5. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60. (Pubitemid 38082153)
6. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther 2003;2:702-6.
7. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res 2005;65:10413-22. (Pubitemid 41743735)
8. Inagaki Y, Xu HL, Nakata M, Seyama Y, Hasegawa K, Sugawara Y, et al. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers. Biosci Trends 2009;3:220-32.
9. Japan Pancreas Society. General rules for the study of pancreatic cancer. 5th edn. Tokyo: Kanehara-syuppan; 2002.
10. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, et al. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 2003;63:5011-20. (Pubitemid 37022639)
11. Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 1988;18:203-16.
12. Kohno N, Inoue Y, Hamada H, Fujioka S, Fujino S, Yokoyama A, et al. Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9. Int J Cancer Suppl 1994;8:81-3. (Pubitemid 24188964)
13. Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated antigen and β-catenin. Mol Cell Biol 1998;18: 7216-24. (Pubitemid 28533041)
14. Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. J Biol Chem 2001;276:35239-42.
15. Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol 2002;26:466-71. (Pubitemid 34280119)
16. Nelson CM, Chen CS. VE-cadherin simultaneously stimulates and inhibits cell proliferation by altering cytoskeletal structure and tension. J Cell Sci 2003;116: 3571-81. (Pubitemid 37063400)
17. Raina D, Kharbanda S, Kufe D. The MUC1 oncopro-tein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004;279:20607-12. (Pubitemid 38656454)
18. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005;128:1606-25. (Pubitemid 40692555)
19. Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ. MUC1 alters betacatenin- dependent tumor formation and promotes cellular invasion. Oncogene 2003;22:1324-32. (Pubitemid 36384593)
20. Sobin LH, Wittekind C. TNM classification of malignant tumors. fifth ed. New York: Wiley-Liss; 1997.
21. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity. J Cell Biol 2001;154:1185-96. (Pubitemid 34286196)
22. Tang W, Inagaki Y, Kokudo N, Guo Q, Seyama Y, Nakata M, et al. KL-6 mucin expression in carcinoma of the ampulla of Vater: association with cancer progression. World J Gastroenterol 2005;11:5450-4. (Pubitemid 41684701)
23. Wen Y, Caffrey TC, Wheelock MJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 2003;278:38029-39. (Pubitemid 37175334)
24. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-65.
25. Xu HL, Inagaki Y, Tang W, Guo Q, Wang FS, Seyama Y, et al. Elevation of serum KL-6 mucin levels in patientswith cholangiocarcinoma. Hepatogastroenterology 2008a;55: 2000-4.
26. Xu HL, Inagaki Y, Wang FS, Nakata M, Kokudo N, Tang W. Effect of benzyl-N-acetyl-α- galactosaminide on KL-6 mucin expression and invasive properties of a human pancreatic carcinoma cell line. Drug Discov Ther 2008b;2:282-5.
27. Xu HL, Inagaki Y, Seyama Y, Sugawara Y, Kokudo N, Nakata M, et al. Expression of KL-6 mucin, a human MUC1 mucin, in intrahepatic cholangiocarcinoma and its potential involvement in tumor cell adhesion and invasion. Life Sci 2009;85:395-400.
28. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003;278:35458-64. (Pubitemid 37102316)
29. Zhang W, Tang W, Inagaki Y, Qiu M, Xu HL, Li X, et al. Positive KL-6 mucin expression combined with decreased membranous beta-catenin expression indicates worse prognosis in colorectal carcinoma. Oncol Rep 2008;20:1013-9.